Current issues in adeno-associated viral vector production

Gene Therapy

Volumn 12, Issue , 2005, Pages S51-S61

  Merten, O W ^a   Geny Fiamma C ^a   Douar, A M ^a  

^a GÉNÉTHON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE; PARVOVIRUS VECTOR;

BACULOVIRUS EXPRESSION SYSTEM; CELL LINE; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; LIVER; MUSCLE; NONHUMAN; PRIORITY JOURNAL; SAFETY; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS GENOME; VIRUS PURIFICATION; VIRUS RECOMBINANT; VIRUS RECOMBINATION;

ANIMALS; BIOREACTORS; BIOTECHNOLOGY; DEPENDOVIRUS; DNA, RECOMBINANT; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MAMMALS; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; HUMAN HERPESVIRUS 1; MIRIDAE; PARVOVIRUS;

EID: 27544445072     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302615     Document Type: Article

References (82)

1. Snyder RO. Adeno-associated virus-mediated gene delivery. J Gene Med 1999; 1: 166-175.
2. Berns KI. Parvoviridae: the virus and their replication. In: Fields BN, Knipe DM, Howley PM (eds) Fields in Virology. Lippincott, Raven: Philadelphia, 1996, pp 2173-2197.
3. Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72: 309-319.
4. Gao GP et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
5. Gao G et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78: 6381-6388.
6. Mori S, Wang L, Takeuchi T, Kanda T. Two novel adeno- associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004; 330: 375-383.
7. Qiu J, Pintel DJ. Alternative polyadenylation of adeno-associated virus type 5 RNA within an internal intron is governed by the distance between the promoter and the intron and is inhibited by U1 small nuclear RNP binding to the intervening donor. J Biol Chem 2004; 279: 14889-14898.
8. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406-411.
9. Tobiasch E et al. Discrimination between different types of human adeno-associated viruses in clinical samples by PCR. J Virol Methods 1998; 71: 17-25.
10. Kotin RM et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87: 2211-2215.
11. Samulski RJ et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941-3950.
12. Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno- associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982; 79: 2077-2081.
13. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987; 61: 3096-3101.
14. Tratschin JD, Miller IL, Smith MG, Carter BJ. Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol Cell Biol 1985; 5: 3251-3260.
15. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281-304.
16. Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adeno- associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol 1984; 51: 611-619.
17. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol 1983; 45: 555-564.
18. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adeno- associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994; 91: 5808-5812.
19. Horer M et al. Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J Virol 1995; 69: 5485-5496.
20. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol 1997; 71: 1079-1088.
21. King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 2001; 20: 3282-3291.
22. Schlehofer JR, Ehrbar M, zur Hausen H. Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus. Virology 1986; 152: 110-117.
23. Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 1991; 65: 2476-2483.
24. McPherson RA, Rosenthal LJ, Rose JA. Human cytomegalovirus completely helps adeno-associated virus replication. Virology 1985; 147: 217-222.
25. Wistuba A et al. Subcellular compartmentalization of adeno- associated virus type 2 assembly. J Virol 1997; 71: 1341-1352.
26. Chiorini JA et al. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1997; 71: 6823-6833.
27. Chiorini JA, Kim F, Yang L, Kotin RM. Cloning and characterization of adeno-associated virus type 5. J Virol 1999; 73: 1309-1319.
28. Xiao W et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994-4003.
29. Snyder RO, Xiao X, Samulski RJ. Production of recombinant adeno-associated viral vectors. In: Dracopoli N, Haines J, Krof B, Moir D, Morton C, Seidman C, Seidman J, Smith D (eds). Current Protocols in Human Genetics. John Wiley and Sons Publisher: New York, 1996, pp 11-24.
30. Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
31. Zolotukhin S et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158-167.
32. Brument N et al. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol Ther 2002; 6: 678-686.
33. Kaludov N, Handelman B, Chiorini JA. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 2002; 13: 1235-1243.
34. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822-3828.
35. Monahan PE et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Therapy 1998; 5: 40-49.
36. Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
37. Salvetti A et al. Factors influencing recombinant adeno-asso- ciated virus production. Hum Gene Ther 1998; 9: 695-706.
38. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
39. Matsushita T et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Therapy 1998; 5: 938-945.
40. Grimm D et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Therapy 1999; 6: 1322-1330.
41. Collaco RF, Cao X, Trempe JP. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999; 238: 397-405.
42. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71: 5236-5243.
43. Vincent KA, Piraino ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J Virol 1997; 71: 1897-1905.
44. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
45. Allen JM, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol 1997; 71: 6816-6822.
46. Schlaeger EJ et al. Transient transfection in mammalian cells. A basic study for an efficient and cost-effective scale up process. In: Merten OW, Perrin P, Griffiths B (eds). New Developments and New Applications in Animal Cell Technology. Kluwer Academic Publishers: Dordrecht, 1998, pp 105-112.
47. Girard P et al. 100-liter transient transfection. Cytotechnology 2002; 38: 15-21.
48. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995; 6: 1329-1341.
49. Blouin V et al. Improving rAAV production and purification: towards the definition of a scaleable process. J Gene Med 2004; 6 (Suppl 1): S223-S228.
50. Gao GP et al. ReplCap gene amplification and high-yield production of AAV in an A549 cell line expressing ReplCap. Mol Ther 2002; 5: 644-649.
51. Tessier J et al. Characterization of adenovirus-induced inverted terminal repeat-independent amplification of integrated adeno-associated virus rep-cap sequences. J Virol 2001; 75: 375-383.
52. Clark KR, Voulgaropoulou F, Johnson PR. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Therapy 1996; 3: 1124-1132.
53. Inoue N, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol 1998; 72: 7024-7031.
54. Fan PD, Dong JY. Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. Hum Gene Ther 1997; 8: 87-98.
55. Gao GP et al. High-titer adeno-associated viral vectors from a ReplCap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9: 2353-2362.
56. Clark KR, Liu X, McGrath JP, Johnson PR. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 1999; 10: 1031-1039.
57. Liu XL, Clark KR, Johnson PR. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Therapy 1999; 6: 293-299.
58. Chadeuf G et al. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J Gene Med 2000; 2: 260-268.
59. Liu X et al. Selective rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol Ther 2000; 2: 394-403.
60. Myers MW, Laughlin CA, Jay FT, Carter BJ. Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2. J Virol 1980; 35: 65-75.
61. Schwarz E et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314: 111-114.
62. Mathews LC, Gray JT, Gallagher MR, Snyder RO. Recombinant adeno-associated viral vector production using stable packaging and producer cell lines. Methods Enzymol 2002; 346: 393-413.
63. Farson D et al. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno- associated viral vectors. J Gene Med 2004; 6: 1369-1381.
64. Toublanc E et al. Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J Gene Med 2004; 6: 555-564.
65. Oualikene W, Lamoureux L, Weber JM, Massie B. Protease- deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy. Hum Gene Ther 2000; 11: 1341-1353.
66. Thorne B. Scaleable processes for rAAV manufacturing. WilBio Meeting on Viral Vectors & Vaccines - Process Development and Production Issues, Las Vegas, NE 2003.
67. Qiao C et al. Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J Virol 2002; 76: 1904-1913.
68. Qiao C et al. A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J Virol 2002; 76: 13015-13027.
69. Conway J et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Therapy 1999; 6: 986-993.
70. Wustner JT et al. Production of recombinant adeno-associated type 5 (rAAV5) vectors using recombinant herpes simplex viruses containing rep and cap. Mol Ther 2002; 6: 510-518.
71. Booth MJ et al. Transfection-free and scalable recombinant AAV vector production using HSVlAAV hybrids. Gene Therapy 2004; 11: 829-837.
72. Blissard GW. Baculovirus-insect cell interactions. Cytotechnology 1996; 20: 73-93.
73. Schmid G. Insect cell cultivation: growth and kinetics. Cytechnol- ogy 1996; 20: 43-55.
74. Kitts PA. Construction of baculovirus recombinants. Cytechnol- ogy 1996; 20: 111-123.
75. Ikonomou L, Schneider Y-J, Agathos SN. Insect cell culture for industrial production of recombinant proteins. Appl Microbiol Biotechnol 2003; 62: 1-20.
76. Maranga L, Cruz PE, Aunins JG, Carrondo MJ. Production of core and virus-like particles with baculovirus infected insect cells. Adv Biochem Eng Biotechnol 2002; 74: 183-206.
77. Casal JI. Parvovirus diagnostics and vaccine production in insect cells. Cytotechnology 1996; 20: 261-270.
78. Ruffing M, Zentgraf H, Kleinschmidt JA. Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J Virol 1992; 66: 6922-6930.
79. Sollerbrant K et al. A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. J Gen Virol 2001; 82: 2051-2060.
80. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13: 1935-1943.
81. Meghrous J et al. Production of recombinant adeno-associated viral vectors using a baculoviruslinsect cell suspension culture system: from shake flasks to a 20-L bioreactor. Biotechnol Prog 2005; 21: 154-160.
82. Rabinowitz JE et al. Cross-packaging of a single adeno- associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801.